[ad_1]
Reporter Yoon So-young, biosviewer
Bunomed Deep Brain AD ™, AI-based brain magnetic resonance imaging. Possible early diagnosis of Alzheimer’s disease
On the 13th, Vuno announced that ‘VUNO Med®-DeepBrain AD ™’ has obtained a grade 3 medical device license from the Ministry of Food and Drug Safety. VunoMed Deepbrain AD ™ is AI-based software that analyzes MRI images of the brain to calculate the probability of Alzheimer’s and reports them in numerical terms.
According to the company, Bunomed Deep Brain AD ™ demonstrated the accuracy of Alzheimer’s diagnosis with AUC (Area Under the Curve) of 0.88 or more in a clinical trial conducted at a large national medical institution. The AUC is a value that represents the correlation between sensitivity and specificity, and the closer to 1, the greater the precision.
Vuno explained that Vunomed DeepBrain AD ™ is a method that overcomes the limitations of the existing PET (Positron Emission Tomography) examination, cerebrospinal fluid examination and MRI examination used for early diagnosis of Alzheimer’s disease. The PET test is expensive, the cerebrospinal fluid test is invasive, and the MRI test has the disadvantage that there is a wide variation in reading.
‘VUNO Med®-DeepBrain®’, an AI-based brain atrophy quantification solution launched by VUNO in June 2019, is a solution that can be used to diagnose degenerative brain diseases, including Alzheimer’s. Vunomed Deep Brain AD ™, which has been approved by the Ministry of Food and Drug Safety, is a program that suggests the possibility of Alzheimer’s and can be used for early diagnosis of Alzheimer’s.
Mr. Hyun-Joon Kim, CEO of Beauno, said: “We are pleased to receive approval from the Ministry of Food and Drug Safety as a third-class medical device that helps in the diagnosis of Alzheimer’s disease, Vero Med Deep Brain AD ™. The great achievements of Buno that have been progressing continuously ”. He added: “We hope that this solution will contribute to the clinical field by analyzing brain MRI, which is widely used for artificial intelligence-based dementia testing, and presents the possibility of Alzheimer’s disease with high precision.”
Meanwhile, Buno is researching and developing artificial intelligence algorithms related to degenerative brain diseases, including dementia. Vunomed Deepbrain®, which quantifies the degree of atrophy of brain regions divided into 100 according to MRI of the brain, obtained approval from the Ministry of Food and Drug Safety in 2018 and CE certification in Europe last year.
Furthermore, VUNO has developed and commercialized 8 medical AI solutions such as ▲ PROMISE-I ▲ VunoMed Funders AI ™ ▲ VunoMed Chest CT AI ™ ▲ VunoMed Chest X-ray ™ ▲ VunoMed Bone Age ™ ▲ VunoMed Deep ASR ™. Five of these solutions have been shown to be effective and safe through clinical trials in large national medical institutions.
[ad_2]
